CSL Aksje

CSL F&U/inntekter

Delisted·19. juni 2026

FoU-forhold til inntekt av CSL (CSL.AX) per 15. aug. 2026 er 8,74 %. Forrige år var FoU-forhold til inntekt 9,66 % — en endring på −9,60% (lavere).

F&U/inntekter

8,74 %

YoY

−9,60%

Sist oppdatert:

FoU-forhold til inntekt av CSL er 2026 8,74 % . FoU-forhold til inntekt av CSL var 2025 9,66 % . Den faller med −9,60% lavere sammenlignet med året før.
Access this data via the Eulerpool API

CSL Aksjeanalyse

Hva gjør CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL er et av de mest populære selskapene på Eulerpool.

Ofte stilte spørsmål om CSL aksje

FoU-forhold til inntekt for CSL er 8,74 % i 2026.

FoU-forhold til inntekt av CSL endret seg fra 9,66 % til 8,74 %, som representerer en −9,60% endring. Verdien er lavere enn forrige år.

På Eulerpool finner du den komplette historiske utviklingen av FoU-forhold til inntekt CSL siden 2006 – med årlige verdier, diagrammer og detaljert analyse.

FoU-forhold til inntekt viser hvilken prosentandel av inntekten et selskap investerer i forskning og utvikling. Høyere forhold indikerer sterkere fokus på innovasjon.

En «god» varierer etter industri og selskapets utviklingsstadium. På Eulerpool kan du sammenligne FoU-forhold til inntekts CSL med sektorkolleger og bransjegjennomsnittet for å vurdere om den er attraktiv.

For å evaluere FoU-forhold til inntekts er det viktig å sammenligne det med konkurrenter i samme industri og sektor. På Eulerpool kan du finne direkte bransjesammenlikninger for FoU-forhold til inntekt.

Access this data via the Eulerpool API

Marginer — CSL

Alle nøkkeltall — CSL